[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-352631-105":59,"doc-detail-352631-en":134},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":127,"head_meta":129,"extra_data":131,"updated_unix":133},105,"en","dars-expression-in-jak2v617f-positive-myeloproliferative-neoplasms-immunohistochemical-analysis-and-clinical-associations","DARS expression in JAK2V617F-positive myeloproliferative neoplasms: immunohistochemical analysis and clinical associations","","Aspartyl-tRNA synthetase (DARS) is implicated in multiple cancers, yet its function in BCR::ABL-negative JAK2V617F-positive myeloproliferative neoplasms remains unclear. The study assessed DARS expression across myeloproliferative neoplasm subtypes and linked it with clinical parameters and survival. Diagnostic bone marrow biopsies from 121 patients were analyzed by immunohistochemistry, generating an IRS. Results showed subtype-specific DARS IRS and inverse associations with spleen size, LDH, and fibrosis grade, while high DARS predicted improved leukemia-free survival independently.",{"@graph":69,"@context":126},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/dars-expression-in-jak2v617f-positive-myeloproliferative-neoplasms-immunohistochemical-analysis-and-clinical-associations/352631/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/dars-expression-in-jak2v617f-positive-myeloproliferative-neoplasms-immunohistochemical-analysis-and-clinical-associations/352631.png","ImageObject",300,407,{"name":92,"@type":93},"Connor ","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-11","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118,122],{"name":109,"@type":110,"acceptedAnswer":111},"What was the goal of this study on DARS in JAK2V617F-positive MPNs?","Question",{"text":112,"@type":113},"To evaluate DARS expression across MPN subtypes and determine associations with clinical parameters and survival.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was DARS expression measured in the patient samples?",{"text":117,"@type":113},"DARS immunoreactivity was assessed in diagnostic bone marrow biopsies by immunohistochemistry using an anti-DARS antibody, and summarized as an IRS from intensity and percentage of positive cells.",{"name":119,"@type":110,"acceptedAnswer":120},"Which clinical features were DARS IRS associated with?",{"text":121,"@type":113},"DARS IRS correlated inversely with spleen size, LDH, and fibrosis grade, and positively with hemoglobin.",{"name":123,"@type":110,"acceptedAnswer":124},"Did DARS expression affect survival outcomes?",{"text":125,"@type":113},"High DARS expression independently predicted improved leukemia-free survival after adjusting for age, subtype, and fibrosis.","https://schema.org",{"og:url":83,"og:type":128,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":130,"canonical":83},"index,follow",{"doc_id":132,"site_id":62},352631,1790829075,{"code":4,"msg":5,"data":135},{"doc_id":132,"user_id":136,"nickname":92,"user_avatar":137,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":143,"language":144,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":145,"faqs":146,"seo_title":147,"seo_description":67,"update_tm":148,"read_time":149,"preview_page_count":19,"preview_urls":150},687207022233,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","Annals of Hematology (2026) 105:209  \n[https://doi.org/10.1007/s00277-026-06934-0](https://doi.org/10.1007/s00277-026-06934-0)  \nRESEARCH  \nDARS expression in JAK2V617F-positive myeloproliferative neoplasms: immunohistochemical analysis and clinical associations  \nAya Mohamed Adel Arafat1 · Heba Adel AbdEl Ghaffar1 · Ahmed M. Khallaf2 ·  \nSufyan Ahmed Mokhtar Younes3 · Mohamed Abdelkader Morad4 · Shirihan Mahmoud Anwar Mahgoub1  \nReceived: 24 October 2025 / Accepted: 2 March 2026 / Published online: 27 March 2026 © The Author(s) 2026  \nAbstract  \nAspartyl-tRNA synthetase (DARS) is implicated in several cancers, but its role in BCR::ABL-negative JAK2V617F-positive myeloproliferative neoplasms (MPNs) is unclear. This study evaluated DARS expression in MPN subtypes and its associations with clinical parameters and survival. Diagnostic bone marrow biopsies from 121 JAK2V617F-positive MPN patients (PV, n = 34; ET, n = 25; PMF, n = 54; MPN-U, n = 8) were stained on a Ventana BenchMark XT immunostainer using antiDARS antibody (ABclonal A6574) . DARS immunoreactive score (IRS) was determined by multiplying intensity (0–3) and percentage of positive cells (0–4) . Inter-observer agreement was excellent (κ = 0.89, 95% CI: 0.83–0.95) . Patients were stratified using the cohort’s median cutoff (IRS = 9) for survival analysis. Statistical tests included Kruskal-Wallis with effect sizes and multivariate Cox regression. DARS IRS differed across subtypes (H = 14.19, p = 0.003, η²=0.10): PV median 9 with IQR (9–12), ET 9 (8–12), PMF 8 (6–9), and MPN-U 10.5 (6–12) . PV vs. PMF differences: intensity p = 0.001 (r = 0.35), IRSp \u003C0.001 (r = 0.38) . DARS IRS correlated inversely with spleen size (ρ=–0.266, p = 0.003, 95% CI: −0.43 to −0.09), LDH (ρ=–0.194, p = 0.033), and fibrosis grade (ρ=–0.280, p = 0.002), and positively with hemoglobin (ρ = 0.308, p = 0.001, 95% CI: 0.13–0.47) . High DARS expression independently predicted improved leukemia-free survival (LFS) (HR = 0.42, p = 0.007, 95% CI: 0.22–0.80) after adjusting for age, subtype, and fibrosis. DARS is differentially expressed in MPN subtypes. Its association with enhanced LFS identifies DARS as a potential prognostic biomarker warranting validation in larger cohorts.  \nKeywords DARS · Myeloproliferative neoplasms · JAK2V617F · Aspartyl-tRNA synthetase · Immunohistochemistry  \nAbbreviations  \nDARS Aspartyl-tRNA synthetase  \nDIPSS Dynamic International Prognostic Scoring System  \nET Essential thrombocythemia  \nIPSET International Prognostic Score for ET IRS Immunoreactive score  \n􀀍 Aya Mohamed Adel Arafat [aya.arafat@kasralainy.edu.eg](aya.arafat@kasralainy.edu.eg)[ ](aya.arafat@kasralainy.edu.eg)HebaAdelAbdEl Ghaffar [heba.adel@kasralainy.edu.eg](heba.adel@kasralainy.edu.eg)[ ](heba.adel@kasralainy.edu.eg)Ahmed M. Khallaf[dr.ahmed201176@med.bsu.edu.eg](dr.ahmed201176@med.bsu.edu.eg)[ ](dr.ahmed201176@med.bsu.edu.eg)Sufyan Ahmed Mokhtar Younes[s.yunus@asmarya.edu.ly](s.yunus@asmarya.edu.ly)[ ](s.yunus@asmarya.edu.ly)Mohamed Abdelkader Morad[dr.m.a.morad@cu.edu.eg](dr.m.a.morad@cu.edu.eg)  \nLDH Lactate dehydrogenase  \nLFS Leukemia-free survival  \nMPN Myeloproliferative neoplasm MPN-U MPN-unclassifiable  \nPMF Primary myelofibrosis PV Polycythemia vera  \nShirihan Mahmoud Anwar Mahgoub  \n[Shirihan.Mahgoub@kasralainy.edu.eg](Shirihan.Mahgoub@kasralainy.edu.eg)  \n1 Department of Clinical and Chemical Pathology, Faculty of Medicine, Cairo University, Cairo, Egypt  \n2 Department of Internal Medicine and Clinical Hematology, Faculty of Medicine, Beni-Suef University, Beni-Suef, Egypt  \n3 Department of Pathology, Faculty of Medicine, Alasmarya Islamic University, Zliten, Libya  \n4 Department of Internal Medicine, Clinical Hematology Unit, Kasr Al Ainy Faculty of Medicine, Cairo University, Cairo, Egypt  \nIntroduction  \nBCR::ABL1-negative myeloproliferative neoplasms (MPNs) represent a group of clonal hematopoietic disorders characterized by excessive proliferation of mature blood cells in the bone marr","cbCaiji4f7xnzVYN","https://ap.wps.com/l/cbCaiji4f7xnzVYN","pdf",3142807,14,"English","# Abstract\n## Study design and cohort\n## Immunohistochemical scoring and statistics\n## Key findings and clinical associations\n## Prognostic implications","[{\"question\":\"What was the goal of this study on DARS in JAK2V617F-positive MPNs?\",\"answer\":\"To evaluate DARS expression across MPN subtypes and determine associations with clinical parameters and survival.\"},{\"question\":\"How was DARS expression measured in the patient samples?\",\"answer\":\"DARS immunoreactivity was assessed in diagnostic bone marrow biopsies by immunohistochemistry using an anti-DARS antibody, and summarized as an IRS from intensity and percentage of positive cells.\"},{\"question\":\"Which clinical features were DARS IRS associated with?\",\"answer\":\"DARS IRS correlated inversely with spleen size, LDH, and fibrosis grade, and positively with hemoglobin.\"},{\"question\":\"Did DARS expression affect survival outcomes?\",\"answer\":\"High DARS expression independently predicted improved leukemia-free survival after adjusting for age, subtype, and fibrosis.\"}]","DARS expression in JAK2V617F-positive myeloproliferative neoplasms: immunohistochemical analysis and clinical associations | PDF",1790100557,35,[151,155,159,163],{"page_no":8,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ecffde7013fa7ee7adc008fb007d64ce.webp",983,1305,{"page_no":14,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6aeb2964562f701891458ebd5d3352e4.webp",982,1304,{"page_no":81,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fcd0cf3e57752c69d3d81f85f29d99ad.webp",981,1303,{"page_no":19,"url":164,"width":165,"height":166},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/23a2adf60a7b16d389cc2d85b3848b4d.webp",980,1301]